Pliant Therapeutics, Inc. Common Stock
PLRXStock
$1.11−19.42%52W
Market Cap$69.04M
P/E—
Div yield—
Beta1.27
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-26.50%
Price vs S&P 500 (4W)-6.48%
VGM Score46.65
Market Capitalization$69.04M
Earnings Surprise History
Q1 26-0.32est. -0.36
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.55
2.55
2.55
2.40
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PLRXPliant Therapeutics, Inc. Common Stock | C | — | D | $1.11 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing oral therapies for fibrotic diseases. Its lead candidate, bexotegrast, is a small-molecule treatment in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company targets significant unmet needs in fibrosis treatment.